Table 6.
Follow-up changes in metabolic biomarkers after chemotherapy among early stage breast cancer patients
| Variable | Pre-treatmenta | Post-treatmenta | Follow-upa | % Change+ | P+ |
|---|---|---|---|---|---|
| Lipid profile | |||||
| Total cholesterol, mg/dL | 185.5 (48.3) | 201.9 (45.5) | 225.8 (56.1) | 10.6 | < 0.01 |
| LDL-C, mg/dL | 100.5 (34.4) | 111.1 (43.7) | 134.5 (45.8) | 17.4 | < 0.01 |
| Glucose metabolism | |||||
| Fasting insulin, mIU/mL | 18.9 (21.8) | 32.6 (17.3) | 36.9 (15.4) | 11.7 | < 0.01 |
| HOMA-IR | 4.52 (1.1) | 9.4 (1.5) | 11.4 (1.3) | 17.5 | < 0.01 |
| HbA1c, % | 5.4 (0.4) | 5.9 (0.6) | 6.7 (0.8) | 11.9 | < 0.01 |
| Inflammation | |||||
| CRP, mg/L | 0.37 (0.36) | 0.49 (0.21) | 0.65 (0.2) | 24.6 | < 0.01 |
LDL-C low-density lipoprotein-cholesterol, HOMA-IR homeostatic model assessment-insulin resistance, HbA1c glycosylated hemoglobin, CRP C-reactive protein
aMean (± SD)
+From post-treatment to follow-up